MedTrace Logo

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

NCT02030301 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2019-02-27

No results posted yet for this study

Summary

The purpose of this study is to test the safety and effectiveness of two experimental therapeutic vaccines against herpes simplex virus, type 2 (HSV-2).

Conditions

  • Genital Herpes Simplex Type 2

Interventions

BIOLOGICAL

VCL-HB01

Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®

BIOLOGICAL

VCL-HM01

Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®

BIOLOGICAL

PBS

Phosphate-buffered saline

Sponsors & Collaborators

  • Vical

    lead INDUSTRY

Principal Investigators

  • Mammen P. Mammen, Jr., MD, FIDSA · Vical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-06-30
Completion
2016-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02030301 on ClinicalTrials.gov